This trial will test the effect of the drug lanifibranor on diabetes control in patients also taking an SGLT2 inhibitor.
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Type 2 Diabetes
1 Primary · 0 Secondary · Reporting Duration: Date of randomisation until the end of treatment at week 24
Side Effects for
3 Treatment Groups
Lanifibranor (IVA337) (800 mg/day)
1 of 3
Lanifibranor (IVA337) (800 mg/day) plus Empagliflozin (10mg/day)
1 of 3
1 of 3
63 Total Participants · 3 Treatment Groups
Primary Treatment: Empagliflozin · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any current vacancies for people who might want to participate in this research?
"The trial you are inquiring about is still recruiting patients, according to the latest information on clinicaltrials.gov. This particular study was posted on 6/29/2022 and updated on 11/3/2022." - Anonymous Online Contributor
What is the regulatory status of Empagliflozin?
"Empagliflozin's safety was rated a 2 because, while there is some data supporting its safety profile, there is no evidence yet of the drug's efficacy." - Anonymous Online Contributor
At how many different geographical locations is this trial taking place?
"There are a total of 14 sites running this clinical trial, which include locations such as the National Research Institute in Huntington Park, Cadena Care Institute in Poway, and Central Virginia VA Healthcare System in Richmond." - Anonymous Online Contributor
How many people are included in this trial?
"In order to complete this study, 63 eligible patients must be recruited. Inventiva Pharma will manage the trial from their facility in Huntington Park, California as well as Cadena Care Institute in Poway, Virginia." - Anonymous Online Contributor